GLUE Monte Rosa Therapeutics, Inc. Common Stock
XNAS
11.22
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
GLUE
$11.22
—
Key stats
$11.22
Pre-market
$11.35
+1.16%
- 52-Week Range
- $8.94 – $25.77
- YTD
- -26.71%
- IV Rank (30D)
- 0.0
- Straddle Price
- $1.73
- P/C Vol Ratio
- 0.22
- Market Cap
- $1.0B
- Open
- $11.38
- Day Range
- $11.09 – $11.74
- Volume
- 1,078,232
- Prev Close
- $11.36
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.57 |
| Cost of Equity (CAPM) | 13.81% (VRP-adj) |
| WACC | 13.80% |
| Volatility Risk Premium | +69.6pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -33.1% |
| Book / Price | 47.4% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -111.7% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $12.73 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $10.75 |
| Bollinger Width / SMA20 | 256.5% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
94%
20-Day Fair Value
≈ by Nov 20, 2026
$11.22
α -0.0%
rank 95%
conviction
3%
40-Day Fair Value
≈ by Dec 21, 2026
$11.67
α +4.0%
rank 95%
conviction
95%
60-Day Fair Value
≈ by Jan 19, 2027
$11.72
α +4.5%
rank 94%
conviction
94%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.1× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.0× · 8 peers |
| Peer P/B | $60.94 | 17% | median 11.5× · 10 peers |
| Peer P/S | $2.05 | 17% | median 6.5× · 9 peers |
| Market Anchor (SMA50) | $12.73 | 67% | stability 78% (BB-width) |
| Options Expected (B-L 30d) | $10.10 | 0% | 8 strikes · skew -1.11 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $1.0B
- Employees
- 173
- List Date
- 2021-06-24
- CIK
- 0001826457
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- ($0.10) (4 est.)
- Headquarters
- Boston, MA
- Homepage
- https://www.monterosatx.com
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for i…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -37.97% | -4.88% | -7.27% | -6.33% | 34.03% | -4.48% |
| Feb | -- | 8.14% | -15.91% | 27.88% | -15.51% | -14.99% | -2.08% |
| Mar | -- | 4.55% | 26.46% | 11.90% | -16.40% | -11.08% | 3.09% |
| Apr | -- | -25.95% | -45.95% | -25.49% | 10.84% | 11.53% | -15.00% |
| May | -- | -35.23% | 40.84% | -30.64% | -14.69% | 4.84% | -6.98% |
| Jun | 7.18% | 33.75% | -9.27% | -6.03% | 0.22% | 23.03% | 8.15% |
| Jul | 10.25% | -10.29% | 9.61% | 14.72% | 7.38% | -31.32% | 0.06% |
| Aug | 39.03% | -6.60% | -14.93% | 41.19% | 0.21% | -9.36% | 8.26% |
| Sep | -40.98% | -1.33% | -22.74% | -8.93% | 50.61% | -16.63% | -6.67% |
| Oct | 16.84% | 21.69% | -24.78% | 60.38% | 71.33% | -0.36%* | 24.18% |
| Nov | -19.17% | -6.09% | -9.36% | 16.40% | 33.97% | -- | 3.15% |
| Dec | 17.29% | -14.40% | 81.09% | -32.09% | -0.63% | -- | 10.25% |
| Total | 7.41% | -63.62% | -37.86% | 20.51% | 131.76% | -24.63% | 5.60% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $10.75
SMA 50: $12.73
SMA 200: $17.81
Current: $11.22
EMA 12: $10.68
EMA 26: $11.35
MACD: -0.6725 | Signal: 0.2581
BEARISH
ADX (14): 34.36
TREND
+DI: 23.76
−DI: 21.91
Momentum Oscillators
RSI (14): 48.00
NEUTRAL
Stoch %K: 59.29
Stoch %D: 37.86
Williams %R: -25.24
Volume & Volatility
BB Upper: $12.23
BB Lower: $9.26
NEUTRAL
OBV: 117,065,535
Vol SMA 20: 1,521,309
Vol ROC: -48.64%
ATR: $0.68
True Range: $0.65
HV 20: 63.7%
HV 30: 59.2%
HV 60: 85.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers:
- Strong bearish momentum signals from MACD and Stochastic indicators
- Negative recent news sentiment, with multiple positive headlines indicating potential for further upside
- High volatility, amplifying market movements
Primary Risks:
- Potential break below lower Bollinger Band and trend line support
- Elevated put/call ratios and open interest in puts indicate bearish sentiment
Investment Thesis: While the stock has shown resilience, the accumulation of bearish momentum signals and negative news sentiment suggests a potential downtrend may be unfolding. However, the recent positive headlines could lead to a brief upside correction.
Recent News Sentiment Impact: The majority of recent news headlines are positive, which could contribute to a short-term bounce. Nevertheless, this upbeat sentiment does not alter the overall bearish trend assessment.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) = Downtrend; Medium-term (1-3 months) = Consolidation; Long-term (3-12 months) = Uptrend
Support/Resistance Levels:
- Lower Bollinger Band: $14.18
- Upper Bollinger Band: $27.55
- SMA 20: $20.87
- SMA 50: $20.46
Momentum Signals: RSI (14): 31.36 (neutral) MACD: -1.61 / Signal: -0.90 / Histogram: -0.71 (bearish)
Volume Analysis: Volume is trending upward, indicating increasing institutional interest and market participation.
News & Sentiment Analysis
Recent Headlines Summary: Multiple positive headlines, including clinical trial updates and investor conference participations.
Sentiment Assessment: Positive news sentiment dominates, with 5 out of 6 recent headlines conveying optimistic tones.
Catalyst Identification: No near-term catalysts identified; focus on market dynamics.
Risk & Volatility Assessment
Beta Interpretation: Beta is close to market average, indicating moderate risk.
Volatility Regime: High volatility amplifies market movements.
Options Market Signals: IV rank indicates medium volatility; put/call ratios and open interest suggest bearish sentiment.
Downside Protection: Support levels at $14.18 and $20.46 could provide downside protection.
Market Context & Positioning
Sector Performance: Monte Rosa Therapeutics is part of the Biotechnology sector, which has been trending upward recently.
Institutional Activity: Volume patterns suggest increasing institutional interest in the stock.
Correlation Analysis: The stock correlates moderately with the market (R-squared: 0.13).
Key Levels & Action Items
Critical Price Levels:
- Support at $14.18 and $20.46
- Resistance at $27.55
Breakout/Breakdown Levels: Break below lower Bollinger Band or SMA 20 could indicate further decline.
Time-Sensitive Catalysts: No near-term catalysts identified; focus on market dynamics.
Risk Management: Consider stop-loss levels around $14.18 and position sizing considerations based on risk tolerance.
Please note that this analysis is not a buy/sell recommendation, but rather a comprehensive assessment of the stock's technical, fundamental, and sentiment factors.
Generated
News
All GLUE news →
Earnings History
13 of 14 under expected move
Avg Expected Move
40.39%
Avg Actual Move
4.53%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-11 | After-Close | 37.78% | 2.91% | 0.08x | Within |
| 2023-11-09 | After-Close | 49.09% | 2.73% | 0.06x | Within |
| 2024-03-14 | After-Close | 42.86% | 5.25% | 0.12x | Within |
| 2024-05-09 | After-Close | 18.92% | 6.37% | 0.34x | Within |
| 2024-08-08 | After-Close | 187.19% | 1.01% | 0.01x | Within |
| 2024-11-07 | After-Close | 14.17% | 2.83% | 0.20x | Within |
| 2025-01-10 | After-Close | 15.79% | 0.70% | 0.04x | Within |
| 2025-03-20 | After-Close | 9.56% | 17.85% | 1.87x | Exceeded |
| 2025-05-08 | Pre-Market | 31.17% | 9.61% | 0.31x | Within |
| 2025-08-07 | After-Close | 74.47% | 3.55% | 0.05x | Within |
| 2025-11-06 | After-Close | 17.10% | 5.38% | 0.31x | Within |
| 2026-03-17 | Pre-Market | 30.73% | 1.96% | 0.06x | Within |
| 2026-05-07 | After-Close | 13.76% | 2.12% | 0.15x | Within |
| 2026-08-06 | After-Close | 22.92% | 1.08% | 0.05x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
GLUE Options Activity & IV Rank
GLUE IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 57.7%
7-DTE IV: —
Expected Move: $1.73
7-DTE Move: $1.73
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 49
Put Volume: 11
P/C Volume: 0.224
BULLISH
Call OI: 5,487
Put OI: 11
P/C OI: 0.002
Total OI: 5,498
ATM Options Pricing
ATM Call: $1.30
ATM Put: $0.42
Call %: 11.6%
Put %: 3.8%
Chain Summary
Chain Volume: 2,375
Chain OI: 8,707
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 87th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
87%
vs own history
GEX tilt
+0.96
OI-weighted, today
Vanna tilt
-0.54
δ-sensitivity to IV
Charm tilt
+0.12
δ-decay vs time
Vanna tilt -0.54: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 8 ATM contracts, 5k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · ATM 53.7% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)0.0LowOct 21
Straddle Price (30 DTE)$1.73Oct 21
Beta Analysis
Risk Metrics
Beta: 1.0852
Alpha: 31.92%
Correlation: 0.1664
R-Squared: 2.8%
Stock Volatility: 82.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own GLUE
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Duquesne Family Office Family office Stanley Druckenmiller | $7.2M | #74 of 86 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $4.0M | #2281 of 6285 | -35.7% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $2.5M | #1843 of 3138 | -73.0% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $128K | #2841 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
GLUE Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 91,707,940 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
9 filers$20.68M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SILVERARC CAPITAL MANAGEMENT, LLC | $7.26M | 35.10% | 2026-06-30 |
| 2 | Caption Management, LLC | $7.26M | 35.10% | 2026-06-30 |
| 3 | DIADEMA PARTNERS LP | $4.12M | 19.90% | 2026-06-30 |
| 4 | Susquehanna International Group, LLP Custodian | $885.72K | 4.28% | 2026-06-30 |
| 5 | DLD Asset Management, LP | $484.20K | 2.34% | 2026-06-30 |
| 6 | Persistent Asset Partners Ltd | $258.07K | 1.25% | 2026-06-30 |
| 7 | Citadel Advisors LLC Custodian | $212.96K | 1.03% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $154.88K | 0.75% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $50.82K | 0.25% | 2026-06-30 |
3 filers$1.43M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.04M | 72.80% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $225.06K | 15.71% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $164.56K | 11.49% | 2026-06-30 |
GLUE Insider Trading (Form 4)
Latest: 2026-10-06Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Matthew Bowen | Principal Accounting Officer | Sell (S) | −13 | $10.56 | -$137 | EDGAR |
| 2026-07-17 | Markus Warmuth | President & CEO | Sell (S) | −9,500 | $23.18 | -$220.2K | EDGAR |
| 2026-07-16 | Jennifer Champoux | Chief Operating Officer | Mixed | — | $13.68 | -$84.4K | EDGAR |
| 2026-07-07 | Sharon Townson | Chief Scientific Officer | Mixed | — | $14.72 | -$103.0K | EDGAR |
| 2026-07-06 | Ali Behbahani | Director | Other (J) | −1,000,000 | — | EDGAR | |
| 2026-07-01 | Filip Janku | Chief Medical Officer | Mixed | — | $18.95 | -$60.0K | EDGAR |
| 2026-06-25 | Sharon Townson | Chief Scientific Officer | Mixed | — | $13.07 | -$41.6K | EDGAR |
| 2026-06-25 | Jennifer Champoux | Chief Operating Officer | Mixed | — | $11.99 | -$34.8K | EDGAR |
| 2026-06-25 | Filip Janku | Chief Medical Officer | Mixed | −5,845 | $14.83 | -$610.0K | EDGAR |
| 2026-06-18 | Sharon Townson | Chief Scientific Officer | Mixed | — | $12.57 | -$38.6K | EDGAR |
| 2026-06-18 | Jennifer Champoux | Chief Operating Officer | Mixed | — | $11.49 | -$32.7K | EDGAR |
| 2026-06-12 | Anthony M. Manning | Director | Grant (A) | +25,800 opt | — | EDGAR | |
| 2026-06-12 | Eric A Hughes | Director | Grant (A) | +25,800 opt | — | EDGAR | |
| 2026-06-12 | Jan Skvarka | Director | Grant (A) | +25,800 opt | — | EDGAR | |
| 2026-06-12 | Andrew N Schiff | Director | Grant (A) | +25,800 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
GLUE Insider Holdings
10 insiders · @ $11.22
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Versant Vantage I GP, L.P. | 10%+ Owner | 5,720,827 | $64.19M | -$53.32M | 2 | 2024-10-30 |
| 2 | Markus Warmuth | President & CEO | 585,038 | $6.56M | -$951.1K | 12 | 2026-07-17 |
| 3 | Sharon Townson | Chief Scientific Officer | 67,845 | $761.2K | -$423.9K | 9 | 2026-07-07 |
| 4 | Jennifer Champoux | Chief Operating Officer | 66,722 | $748.6K | -$311.3K | 8 | 2026-07-16 |
| 5 | Filip Janku | Chief Medical Officer | 60,612 | $680.1K | -$1.24M | 12 | 2026-07-01 |
| 6 | Philip Nickson | Chief Business & Legal Officer | 55,000 | $617.1K | -$151.3K | 7 | 2026-04-10 |
| 7 | Matthew Bowen | Principal Accounting Officer | 25,891 | $290.5K | -$137 | 2 | 2026-10-06 |
| 8 | Edmund Dunn | Principal Accounting Officer | 22,554 | $253.1K | -$503.4K | 8 | 2026-03-05 |
| 9 | Anthony M. Manning | Director | 10,000 | $112.2K | -$180.1K | 5 | 2026-06-12 |
| 10 | Chandra P. Leo | Director | 10,000 | $112.2K | $58.4K | 2 | 2025-03-25 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
GLUE Board & Officers
As of SEC filings through Oct 6, 2026Directors 9
- Ali Behbahani · since Jun 23, 2021
- Andrew N Schiff · since Jun 23, 2021
- Chandra P. Leo · since Jun 23, 2021
- Christine Siu · since Jun 23, 2021
- Kimberly Blackwell · since Jun 23, 2021
- Markus Warmuth · since Jun 23, 2021
- Jan Skvarka · since Mar 23, 2023
- Anthony M. Manning · since Jul 25, 2023
- Eric A Hughes · since Dec 11, 2024
Officers 6
- Markus Warmuth · President & CEO · since Jun 23, 2021
- Jennifer Champoux · Chief Operating Officer · since May 28, 2024
- Filip Janku · Chief Medical Officer · since Jun 23, 2021
- Philip Nickson · Chief Business & Legal Officer · listed since Jun 2024
- Sharon Townson · Chief Scientific Officer · listed since Jun 2024
- Matthew Bowen · Principal Accounting Officer · since Apr 3, 2026
Changes in the last 10 years (67)
| Jun 12, 2026 | Ali Behbahani no longer listed as a 10% owner in SEC filings |
| Apr 3, 2026 | Matthew Bowen became Principal Accounting Officer |
| Jan 9, 2026 | The company announced the departure of Edmund Dunn as Principal Accounting Officer in an SEC filing |
| Dec 11, 2024 | Eric A Hughes became a director |
| Oct 30, 2024 | Versant Ventures VI GP-GP, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 30, 2024 | Versant Ventures VI GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 30, 2024 | Versant Venture Capital VI, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 30, 2024 | Versant Vantage I, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 30, 2024 | Versant Vantage I GP-GP, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 30, 2024 | Versant Vantage I GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 5, 2024 | Sharon Townson listed as Chief Scientific Officer (previously Chief Technology Officer) in SEC filings |
| Jun 5, 2024 | Philip Nickson listed as Chief Business & Legal Officer (previously General Counsel) in SEC filings |
| May 28, 2024 | Jennifer Champoux became Chief Operating Officer |
| Apr 29, 2024 | The company announced the departure of Owen B. Wallace as Chief Scientific Officer in an SEC filing |
| Aug 8, 2023 | Edmund Dunn became Principal Accounting Officer |
| Jul 25, 2023 | Anthony M. Manning became a director |
| Mar 23, 2023 | Jan Skvarka became a director |
| Mar 1, 2022 | Philip Nickson became General Counsel |
| Dec 1, 2021 | Jullian G Jones became Chief Business Officer |
| Jun 30, 2021 | Cormorant Private Healthcare Fund III LP reported in an SEC filing no longer being a 10% owner |
| Jun 30, 2021 | Cormorant Private Healthcare Fund II, LP reported in an SEC filing no longer being a 10% owner |
| Jun 30, 2021 | Cormorant Global Healthcare Master Fund, LP reported in an SEC filing no longer being a 10% owner |
| Jun 30, 2021 | Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner |
| Jun 30, 2021 | Bihua Chen reported in an SEC filing no longer being a director |
| Jun 30, 2021 | Bihua Chen reported in an SEC filing no longer being a 10% owner |
| Jun 23, 2021 | Versant Ventures VI GP-GP, LLC became a 10% owner |
| Jun 23, 2021 | Versant Ventures VI GP, L.P. became a 10% owner |
| Jun 23, 2021 | Versant Venture Capital VI, L.P. became a 10% owner |
| Jun 23, 2021 | Versant Vantage I, L.P. became a 10% owner |
| Jun 23, 2021 | Versant Vantage I GP-GP, LLC became a 10% owner |
| Jun 23, 2021 | Versant Vantage I GP, L.P. became a 10% owner |
| Jun 23, 2021 | Sharon Townson became Chief Technology Officer |
| Jun 23, 2021 | Scott D Sandell became a 10% owner |
| Jun 23, 2021 | Rick Yang became a 10% owner |
| Jun 23, 2021 | Peter W. Sonsini became a 10% owner |
| Jun 23, 2021 | Paul Edward Walker became a 10% owner |
| Jun 23, 2021 | Owen B. Wallace became Chief Scientific Officer |
| Jun 23, 2021 | New Enterprise Associates 17, L.P. became a 10% owner |
| Jun 23, 2021 | Nea 17 Gp, LLC became a 10% owner |
| Jun 23, 2021 | NEA Partners 17, L.P. became a 10% owner |
| Jun 23, 2021 | Mohamad Makhzoumi became a 10% owner |
| Jun 23, 2021 | Markus Warmuth became a director |
| Jun 23, 2021 | Markus Warmuth became President & CEO |
| Jun 23, 2021 | Liza Landsman became a 10% owner |
| Jun 23, 2021 | Kimberly Blackwell became a director |
| Jun 23, 2021 | Joshua Makower became a 10% owner |
| Jun 23, 2021 | John C. Castle became Chief Data Scientist |
| Jun 23, 2021 | Forest Baskett became a 10% owner |
| Jun 23, 2021 | Filip Janku became Chief Medical Officer |
| Jun 23, 2021 | Edward T Mathers became a 10% owner |
| Jun 23, 2021 | Cormorant Private Healthcare Fund III LP became a 10% owner |
| Jun 23, 2021 | Cormorant Private Healthcare Fund II, LP became a 10% owner |
| Jun 23, 2021 | Cormorant Global Healthcare Master Fund, LP became a 10% owner |
| Jun 23, 2021 | Cormorant Asset Management, LP became a 10% owner |
| Jun 23, 2021 | Christine Siu became a director |
| Jun 23, 2021 | Chandra P. Leo became a director |
| Jun 23, 2021 | Carmen Chang became a 10% owner |
| Jun 23, 2021 | Bradley J PhD Bolzon became a director |
| Jun 23, 2021 | Bradley J PhD Bolzon became a 10% owner |
| Jun 23, 2021 | Bihua Chen became a director |
| Jun 23, 2021 | Bihua Chen became a 10% owner |
| Jun 23, 2021 | Anthony A. Florence Jr. became a 10% owner |
| Jun 23, 2021 | Andrew N Schiff became a director |
| Jun 23, 2021 | Ali Behbahani became a director |
| Jun 23, 2021 | Ali Behbahani became a 10% owner |
| Jun 23, 2021 | Alexander Mayweg became a director |
| Jun 23, 2021 | Ajim Tamboli became Chief Financial Officer |
Not reported recently (19)
- Jullian G Jones · Last reported as Chief Business Officer in an SEC filing dated Jan 4, 2024
- Alexander Mayweg · Last reported as a director in an SEC filing dated Jun 15, 2023
- Ajim Tamboli · Last reported as Chief Financial Officer in an SEC filing dated Jan 4, 2023
- John C. Castle · Last reported as Chief Data Scientist in an SEC filing dated Jan 4, 2023
- Rick Yang · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Scott D Sandell · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Paul Edward Walker · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Peter W. Sonsini · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Edward T Mathers · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Joshua Makower · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Mohamad Makhzoumi · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Anthony A. Florence Jr. · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Liza Landsman · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Carmen Chang · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- NEA Partners 17, L.P. · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Forest Baskett · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- New Enterprise Associates 17, L.P. · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Nea 17 Gp, LLC · Last reported as a 10% owner in an SEC filing dated Jun 30, 2021
- Bradley J PhD Bolzon · Last reported as a director in an SEC filing dated Jun 30, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
GLUE Proposed Insider Sales (Form 144)
Latest: 2026-07-16
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-16 | MARKUS WARMUTH | Officer | 9,500 | $220.2K | 2026-07-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-07-15 | Champoux Jennifer | Officer | 4,351 | $101.7K | 2026-07-15 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-06-30 | FILIP JANKU | Officer | 5,407 | $129.2K | 2026-06-30 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-29 | FILIP JANKU | Officer | 6,000 | $133.7K | 2026-06-29 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-29 | ANTHONY M MANNING | Director | 10,000 | $231.1K | 2026-06-29 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-24 | FILIP JANKU | Officer | 30,000 | $621.3K | 2026-06-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-23 | Champoux Jennifer | Officer | 2,175 | $40.0K | 2026-06-23 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-06-23 | FILIP JANKU | Officer | 11,845 | $221.1K | 2026-06-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-23 | EDMUND DUNN | Officer | 16,665 | $345.0K | 2026-06-23 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-17 | Champoux Jennifer | Officer | 2,176 | $39.0K | 2026-06-17 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
60 ETFs hold GLUE
25 shown · $155.52M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $30.6M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.24% | $24.9M | $10.4B | 2026-10-20 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $21.3M | $75.1B | 2026-10-20 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $10.0M | — | 2026-09-30 |
| 5 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.33% | $8.0M | — | 2026-06-30 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.06% | $7.8M | $13.6B | 2026-10-20 |
| 7 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.03% | $5.9M | — | 2026-05-31 |
| 8 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.21% | $5.8M | — | 2026-06-30 |
| 9 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.05% | $5.2M | $11.0B | 2026-10-20 |
| 10 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $5.1M | — | 2026-09-30 |
| 11 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $4.8M | — | 2026-10-20 |
| 12 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.01% | $4.3M | $31.4B | 2026-10-20 |
| 13 | USVM VictoryShares US Small Mid Cap Value Momentum ETF | Nport | 0.19% | $3.3M | — | 2026-06-30 |
| 14 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.05% | $3.2M | $6.6B | 2026-10-20 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $2.7M | — | 2026-10-20 |
| 16 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.21% | $2.6M | $1.2B | 2026-10-20 |
| 17 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.7M | — | 2026-09-30 |
| 18 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.6M | — | 2026-10-20 |
| 19 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.04% | $1.4M | $3.1B | 2026-10-20 |
| 20 | PSC Principal U.S. Small-Cap ETF | Nport | 0.04% | $1.0M | — | 2026-06-30 |
| 21 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.0M | $97.4B | 2026-10-20 |
| 22 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.16% | $1.0M | — | 2026-10-21 |
| 23 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.06% | $959,924 | — | 2026-09-30 |
| 24 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.03% | $801,121 | — | 2026-07-31 |
| 25 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $700,079 | — | 2026-05-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.76
TTM Revenue
$28.73M
TTM Net Income
$-161.12M
TTM Op. Cash Flow
$-24.07M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $8.97M | $-43.40M | $-0.43 | $-44.11M |
| Q1 '26 | 2026-03-31 | $4.21M | $-44.50M | $-0.45 | $-37.37M |
| Q4 '25 | 2025-12-31 | $2.78M | $-46.13M | $-0.55 | $-43.01M |
| Q3 '25 | 2025-09-30 | $12.77M | $-27.08M | $-0.33 | $100.43M |
| Q2 '25 | 2025-06-30 | $23.19M | $-12.29M | $-0.15 | $-34.72M |
| Q1 '25 | 2025-03-31 | $84.93M | $46.88M | $0.57 | $-45.49M |
| Q4 '24 | 2024-12-31 | $60.65M | $13.44M | $0.23 | $128.92M |
| Q3 '24 | 2024-09-30 | $9.22M | $-23.86M | $-0.29 | $-20.99M |
| Q2 '24 | 2024-06-30 | $4.70M | $-30.31M | $-0.43 | $-27.77M |
| Q1 '24 | 2024-03-31 | $1.06M | $-31.97M | $-0.53 | $-38.16M |
| Q4 '23 | 2023-12-31 | — | $-33.25M | $-0.57 | $29.63M |
| Q3 '23 | 2023-09-30 | — | $-34.88M | $-0.70 | $-24.71M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.11
P/S
35.82
EV/EBITDA
—
EV/Sales
32.68
ROE
-33.1%
ROA
-23.3%
Div Yield
0.00%
FCF Yield
-2.34%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.03B
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
19.69M
SI % of Float
39.92%
Days to Cover
18.00
Short Vol Ratio
45.8%
Free Float
49.32M
Float %
75.7%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-02-17